tbuckley/cabot-search huggingface dataset:
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <scp>MASK</scp> study
Authors: J. Bousquet, P. Devillier, J. M. Anto, M. Bewick, T. Haahtela, S. Arnavielhe, A. Bedbrook, R. Murray, M. van Eerd, J. A. Fonseca, M. Morais Almeida, A. Todo Bom, E. Menditto, G. Passalacqua, C. Stellato, M. Triggiani, M. T. Ventura, G. Vezzani, I. Annesi‐Maesano, R. Bourret, I. Bosse, D. Caimmi, C. Cartier, P. Demoly, J. Just, F. Portejoie, V. Siroux, F. Viart, K. C. Bergmann, T. Keil, L. Klimek, R. Mösges, O. Pfaar, S. Shamai, T. Zuberbier, J. Mullol, A. Valero, O. Spranger, P. V. Tomazic, M. L. Kowalski, P. Kuna, M. Kupczyk, F. Raciborski, B. Samolinski, S. K. Toppila‐Salmi, E. Valovirta, A. A. Cruz, F. Sarquis‐Serpa, J. da Silva, R. Stelmach, D. Larenas‐Linnemann, M. Rodriguez Gonzalez, M. T. Burguete Cabañas, V. Kvedariene, A. Valiulis, N. H. Chavannes, W. J. Fokkens, D. Ryan, A. Sheikh, C. Bachert, P. W. Hellings, O. VandenPlas, N. Ballardini, I. Kull, E. Melén, M. Westman, M. Wickman, C. Bindslev‐Jensen, E. Eller, S. Bosnic‐Anticevich, R. E. O'Hehir, I. Agache, T. Bieber, T. Casale, B. Gemicioğlu, J. C. Ivancevich, G. De Vries, M. Sorensen, A. Yorgancioglu, D. Laune
Journal: Allergy (2018)

Abstract Background Multimorbidity in allergic airway diseases is well known, but no data exist about the daily dynamics of symptoms and their impact on work. To better understand this, we aimed to assess the presence and control of daily allergic multimorbidity (asthma, conjunctivitis, rhinitis) and its impact on work productivity using a mobile technology, the Allergy Diary . Methods We undertook a 1‐year prospective observational study in which 4 210 users and 32 585 days were monitored in 19 countries. Five visual analogue scales (VAS) assessed the daily burden of the disease (i.e., global evaluation, nose, eyes, asthma and work). Visual analogue scale levels &lt;20/100 were categorized as “Low” burden and VAS levels ≥50/100 as “High” burden. Results Visual analogue scales global measured levels assessing the global control of the allergic disease were significantly associated with allergic multimorbidity. Eight hypothesis‐driven patterns were defined based on “Low” and “High” VAS levels. There were &lt;0.2% days of Rhinitis Low and Asthma High or Conjunctivitis High patterns. There were 5.9% days with a Rhinitis High—Asthma Low pattern. There were 1.7% days with a Rhinitis High—Asthma High—Conjunctivitis Low pattern. A novel Rhinitis High—Asthma High—Conjunctivitis High pattern was identified in 2.9% days and had the greatest impact on uncontrolled VAS global measured and impaired work productivity. Work productivity was significantly correlated with VAS global measured levels. Conclusions In a novel approach examining daily symptoms with mobile technology, we found considerable intra‐individual variability of allergic multimorbidity including a previously unrecognized extreme pattern of uncontrolled multimorbidity.
Editor’s Choice: Clerical and medical
Authors: Tom Moberly
Journal: BMJ (2016)

Cost cutting has gone by many names in recent years. From “austerity” and “rationalisation” to “efficiency savings” and “savings,” the health service is well used to euphemisms for “cuts.” Rachel Hooke pulls up another phrase to add to this lexicon: “admin and clerical review” http://careers.bmj.com/careers/advice/In\_support\_of\_medical\_secretaries. She says, “This usually means cost …
Abstract 915: Deletion of <i>JNK2</i> Prevents Hypercholesterolemia-Induced Oxidative Stress and Endothelial Dysfunction
Authors: Elena Osto, Christian M Matter, Alexey Kuroedov, Giovanni Camici, Tadeusz Malinski, Markus Bachschmid, Thomas Stallmach, Jan Boren, Sabino Iliceto, Thomas F Luscher, Francesco Cosentino
Journal: Circulation (2007)

Background Hypercholesterolemia-induced endothelial dysfunction (ED) is a major trigger for atherosclerosis. The c-Jun-N-terminal kinases (JNKs) belong to the mitogen-activated protein kinase family. Genetic deletion of JNK2 has been shown to decrease atheroma formation. The present study was designed to investigate whether hypercholesterolemic JNK2 knockout ( JNK2 −/− ) mice are protected from oxidative stress-induced ED. Methods and Results Male JNK2 −/− and corresponding wild-type (WT) mice (8 weeks old) were fed either a high cholesterol diet (HCD, 1.25% total cholesterol) or normal chow (controls) for 14 weeks. WT mice fed a HCD showed a 2-fold increase in JNK phosphorylation as assessed by Western blotting (n=4 – 6, p&lt;0.05 vs. controls). In parallel, endothelium-dependent relaxations to acetylcholine (Ach, 10 −9 -10 −6 mol/L) were impaired in WT mice exposed to a HCD as compared to WT controls (n=4 – 6 in each groups, p&lt;0.05). In contrast, JNK2 −/− mice did not exhibit hypercholesterolemia-induced ED (96±5% max relaxation to Ach, n=4 – 6, p&lt;0.05 vs. WT HCD). Endothelium-independent relaxations to sodium nitroprusside (10 −10 -10 −5 mol/L) were identical in all groups. Nitric oxide release, measured by nanosensors in single aortic endothelial cells, was decreased in WT but not in JNK2 −/− HCD mice (121 vs. 253 nmol/L in WT and JNK2 −/− HCD mice, respectively, n=4 – 6, p&lt;0.05). Indeed, WT HCD mice displayed a marked increase in peroxynitrite (ONOO − ) generation, nitrotyrosine expression,and lipid peroxidation (n=4 – 6 in each groups, p&lt;0.05 vs. WT and JNK2 −/− control as well as JNK2 −/− HCD mice). Deletion of the JNK2 gene prevented this hypercholesterolemia-induced increase in oxidative stress. Furthermore, expression of antioxidant defense systems such as manganese and extracellular superoxide dismutase as well as heme-oxygenase activity was significantly decreased in WT, but not in JNK2 −/− HCD mice (n=4 – 6, p&lt;0.05). Conclusions These data suggest that genetic deletion of JNK2 protects against hypercholesterolemia-induced oxidative stress and endothelial dysfunction. Thus, inhibition of JNK2 may represent a novel therapeutic target to prevent initiation of atherogenesis.
Where can I find past Career Focus articles?
Authors: Rhona MacDonald
Journal: BMJ (2004)

<i>Got a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone (www.bmjcareers.com/advicezone) for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site.</i>
Staff engagement should be as important as clinical outcomes and patient safety, says King’s Fund
Authors: Abi Rimmer
Journal: BMJ (2015)

Staff engagement should be as important to NHS boards as patients’ safety and clinical outcomes, the King’s Fund has said.

A report on staff engagement by Ben Collins, project director at the King’s Fund, set out the six “building blocks” needed to encourage staff engagement in the NHS.1

NHS providers with high levels of staff engagement, as measured in the annual NHS staff survey, have lower levels of patient …
Initiating Phototherapy at Subthreshold Levels
Authors: James A. Taylor, Pearl W. Chang
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
I will complete my postgraduate degree (MD in anaesthesia) in India in March 2006, and I have passed the Professional and Linguistic Assessments Board test part 2. However, the current situation for overseas doctors in the UK and the development of super specialties in the field of anaesthesia in India is making me think twice before I move to the UK. What should I do?
Authors: Peter Shirley
Journal: BMJ (2006)

Have a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site. <b>www.bmjcareers.com/advicezone</b>
Low frequency of acetyl salicylic acid hypersensitivity in mastocytosis: The results of a double‐blind, placebo‐controlled challenge study
Authors: M. A. W. Hermans, S. Q. A. van der Vet, P. M. van Hagen, R. Gerth van Wijk, P. L. A. van Daele
Journal: Allergy (2018)

Abstract Background Patients with mastocytosis are at increased risk of anaphylaxis. The use of nonsteroidal anti‐inflammatory drugs ( NSAID s) is often discouraged because of this reason. However, the actual prevalence and severity of NSAID ‐related hypersensitivity among patients with mastocytosis is unknown. Methods A double‐blind, placebo‐controlled acetylsalicylic acid ( ASA ) challenge up to a cumulative dose of 520 mg was performed among adult patients with mastocytosis. In addition, a retrospective search of the entire outpatient cohort was performed to obtain “real‐life” data on NSAID hypersensitivity. Results Fifty patients underwent an ASA challenge. Seventy percent had indolent systemic mastocytosis, 18% had mastocytosis in the skin, and 12% had advanced mastocytosis. The ASA challenge was positive in 1 patient who developed urticaria. The additional retrospective chart review revealed that 8 of 191 patients had a history of NSAID ‐related hypersensitivity reaction(s), of whom 3 reported severe systemic reactions. All 8 patients had already experienced NSAID ‐related hypersensitivity reactions before mastocytosis was diagnosed. Conclusions The frequency of ASA hypersensitivity was 2% in a prospective challenge study and 4.1% in a retrospective chart review of 191 patients with mastocytosis. NSAID s can be administered safely to most patients with mastocytosis. Extra caution should be taken in patients with a history of hypersensitivity reactions to other drugs, or traditional risk factors for NSAID hypersensitivity.
Psychiatry may need run-through training programmes, says Centre for Workforce Intelligence
Authors: Abi Rimmer
Journal: BMJ (2014)

Health Education England (HEE) should consider creating run-through training programmes for old age, general adult, and child and adolescent psychiatry, the Centre for Workforce Intelligence has said.

In its in-depth review of the psychiatrist workforce, the centre said that although the number of consultant psychiatrists had grown in the past decade it was proportionally 10% lower than the overall growth in consultant numbers in England.1

The report said that more consultant psychiatrists aged over 53 left the workforce than consultants as a whole …
Safety of Multiple Antigen Exposure in the Childhood Immunization Schedule
Authors: Sean T. O’Leary, Yvonne A. Maldonado
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ASSOCIATION OF SEX WITH ATHEROSCLEROTIC PLAQUE CHARACTERISTICS IN PRECURSORS OF CULPRIT LESIONS: THE ICONIC STUDY
Authors: Aeshita Dwivedi, Leslee Shaw, Fay Lin, Jessica Pena, Daniele Andreini, Filippo Cademartiri, Kavitha Chinnaiyan, Benjamin Chow, Ricardo Cury, Gudrun Feuchtner, Martin Hadamitzky, Yong-Jin Kim, Jonathon Leipsic, Hugo Marques, Gianluca Pontone, Todd Villines, Peter Stone, Habib Samady, Renu Virmani, Jagat Narula, Jeroen J. Bax, James K. Min, Hyuk-Jae Chang
Journal: Journal of the American College of Cardiology (2018)
Abstract ES8-1: Liquid biopsies in breast cancer - challenges and opportunities
Authors: S-J Dawson
Journal: Cancer Research (2018)

Abstract Cell-free circulating DNA containing tumor-specific sequences can be identified in the plasma of cancer patients, providing a liquid biopsy alternative to tissue biopsies for monitoring cancer genetic changes over time. Circulating tumor DNA (ctDNA) analysis can allow real-time monitoring of tumor dynamics and treatment response from a simple blood test that is safe, reliable and easy to perform at regular intervals during therapy. Serial analysis of ctDNA provides a unique opportunity to study the evolving genomic landscape of a cancer during therapy, identify the early emergence of treatment resistance and guide targeted therapeutic decisions. The use of ctDNA for molecular disease monitoring has the potential to facilitate precision medicine and optimize cancer management across a range of malignancies. A summary of current approaches for ctDNA analysis will be presented, together with an overview of clinical applications for the use of liquid biopsies in breast cancer management. Citation Format: Dawson S-J. Liquid biopsies in breast cancer - challenges and opportunities [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr ES8-1.
Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population
Authors: Y. Fujisawa, K. Yoshino, A. Otsuka, T. Funakoshi, T. Fujimura, Y. Yamamoto, H. Hata, R. Tanaka, K. Yamaguchi, Y. Nonomura, I. Hirai, S. Furudate, H. Okuhira, K. Imafuku, M. Aoki, S. Matsushita
Journal: British Journal of Dermatology (2018)
Impact of hypertension on recurrence and survival of patients with renal cell carcinoma after surgery.
Authors: Takahito Suyama, Manato Kanesaka, Kotaro Otsuka, Ayumi Fujimoto, Kyokushin Hou, Tomonori Kato, Kazuhiro Araki, Hiroshi Masuda, Satoko Kojima, Yukio Naya
Journal: Journal of Clinical Oncology (2018)

611 Background: Hypertension (HT) is an established risk factor for developing renal cell carcinoma (RCC), and a relationship between the renin-angiotensin system and RCC has been emphasized. However, information about the impact of HT on treatment outcomes of patients after RCC surgery is limited. The present study aimed to clarify the impact of HT on the recurrence and survival of patients with RCC after surgery. Methods: Relationships between HT and clinical data including treatment outcomes were retrospectively analyzed in 149 patients (male, n = 112; female, n = 37; median age, 63 y; range, 29-86 y at the time of surgery) who underwent surgery between 2010 and 2016 at our hospital. Data were statistically analyzed using JMP version 9.0. Results: During a median follow-up period of 30.9 months, 28 and 16 patients experienced recurrence and died, respectively. Patients (n = 15) with Stage IV RCC were excluded from the analysis of recurrence. Five-year overall (OS) and recurrence-free (RFS) survival rates of the entire cohort were 80.8% and 76.1%, respectively. Kaplan-Meier analysis did not uncover a relationship between HT and OS, but the RFS rate was significantly lower for patients with HT than without HT (P = 0.0468). Tumor stage and the prevalence of proteinuria were significantly higher in the group with HT. The prevalences of vessel invasion (P = 0.0582) and low pre-surgical hemoglobin values (P = 0.0585) tended to be significantly higher for patients with HT. Conclusions: Patients with HT had significantly worse RFS rates, a more advanced stage of disease at the time of surgery, and a tendency towards a higher rate of vessel invasion. Further investigations are warranted to determine how HT promotes cancer progression.
Production-scale fibronectin nanofibers promote wound closure and tissue repair in a dermal mouse model
Authors: Christophe O. Chantre, Patrick H. Campbell, Holly M. Golecki, Adrian T. Buganza, Andrew K. Capulli, Leila F. Deravi, Stephanie Dauth, Sean P. Sheehy, Jeffrey A. Paten, Karl Gledhill, Yanne S. Doucet, Hasan E. Abaci, Seungkuk Ahn, Benjamin D. Pope, Jeffrey W. Ruberti, Simon P. Hoerstrup, Angela M. Christiano, Kevin Kit Parker
Journal: Biomaterials (2018)
Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints
Authors: Nicolas Gourdin, Marion Bossennec, Céline Rodriguez, Selena Vigano, Christelle Machon, Camilla Jandus, David Bauché, Julien Faget, Isabelle Durand, Nicolas Chopin, Olivier Tredan, Julien C. Marie, Bertrand Dubois, Jérôme Guitton, Pedro Romero, Christophe Caux, Christine Ménétrier-Caux
Journal: Cancer Research (2018)

Abstract The production of CD73-derived adenosine (Ado) by Tregs has been proposed as a resistance mechanism to anti-PD-1 therapy in murine tumor models. We reported that human Tregs express the ectonucleotidase CD39, which generates AMP from ATP, but do not express the AMPase CD73. In contrast, CD73 defined a subset of effector CD4+ T cells (Teffs) enriched in polyfunctional Th1.17 cells characterized by expression of CXCR3, CCR6, and MDR1, and production of IL17A/IFNγ/IL22/GM-CSF. CD39+ Tregs selectively targeted CD73+ Teffs through cooperative degradation of ATP into Ado inhibiting and restricting the ability of CD73+ Teffs to secrete IL17A. CD73+ Teffs infiltrating breast and ovarian tumors were functionally blunted by Tregs expressing upregulated levels of CD39 and ATPase activity. Moreover, tumor-infiltrating CD73+ Teffs failed to express inhibitory immune checkpoints, suggesting that CD73 might be selected under pressure from immune checkpoint blockade therapy and thus may represent a nonredundant target for restoring antitumor immunity. Significance: Polyfunctional CD73+ T-cell effectors lacking other immune checkpoints are selectively targeted by CD39 overexpressing Tregs that dominate the breast tumor environment. Cancer Res; 78(13); 3604–18. ©2018 AACR.
Pancreatic Neuroendocrine Tumor With Involvement of the Inferior Mesenteric Vein Diagnosed by Ga-68 DOTA-TATE PET/CT
Authors: Aurora Sainz-Esteban, Vikas Prasad, Richard P Baum
Journal: Clinical Nuclear Medicine (2009)

It has been reported that benign and malignant thrombi may be distinguishable by its F-18 fluorodeoxyglucose uptake on PET, the malignant thrombus having a higher uptake as compared with the benign. Tumor thrombus may involve the portal vein and inferior vena cava in patients with abdominal or pelvic malignancy. We present a case of a pancreatic neuroendocrine tumor with hepatic and regional lymph node metastases and with an uptake pattern along the inferior mesenteric vein on Ga-68 DOTA-TATE PET/CT similar to those reported for a malignant tumor thrombus diagnosed with F-18 FDG PET/CT.
Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA).
Authors: Daniel Khalaf, Cameron Herberts, Gillian Vandekerkhove, Matti Annala, Kevin Beja, Bernhard J. Eigl, Christian K. Kollmannsberger, Lucia Nappi, Joanna Vergidis, Alexander William Wyatt, Kim N. Chi
Journal: Journal of Clinical Oncology (2018)

260 Background: Docetaxel is associated with improved outcomes for mCRPC. There are currently no predictive molecular biomarkers for docetaxel to assist with patient selection. Methods: Patients commencing docetaxel for mCRPC between November 2015 and August 2017 were enrolled on a prospective cohort study evaluating circulating biomarkers. A plasma sample for ctDNA analysis was collected before initiation of docetaxel. Targeted sequencing of 73 prostate cancer-relevant genes was performed on leukocyte DNA (germline) and plasma cell-free DNA. Patient records were reviewed for baseline clinical characteristics, PSA response (≥ 50% decline from baseline), and time to PSA progression (TTPP) (PCWG3 criteria). Results: There were 33 patients enrolled; all patients had received prior abiraterone or enzalutamide and none had received prior taxanes. At baseline, the median age was 69.9 years, 30.3% had ECOG performance status 2, 66.7% had bone metastasis and 9.1% had liver metastases. The PSA response rate (RR) was 39.4% and 33.3% had a TTPP less than 3 months. 82% of patients had a ctDNA fraction &gt;5%. Deleterious BRCA2 or ATM defects were present in 12.1% (4/33) of patients (3 somatic and 1 germline). TP53 alterations were identified in 39.4% (13/33), RB1 loss in 21.2% (7/33), PTEN loss in 21.2% (7/33), and Androgen Receptor (AR) amplification in 42.2% (14/33). PTEN deletion was associated with a trend toward inferior RR and TP53 had no discernible effect on PSA RR (Table). BRCA2/ATM defects were associated with a trend toward a lower rate of PSA progression within 3 months (Table). Conclusions: In this preliminary analysis, TP53 alterations had no discernible effect on efficacy of docetaxel chemotherapy. Accrual is ongoing in order to further clarify whether there is an association between PTEN, RB1, AR and BRCA2/ATM alterations and benefit from docetaxel. [Table: see text]
Miles W Carroll replies to Deborah Cohen
Authors: Miles W Carroll
Journal: BMJ (2018)

Cohen discussed a study performed at the Health Protection Agency, now Public Health England, in her article about vaccine research and the role of preclinical studies.1 Public Health England has responded to all requests for information about this study, but in the interest of clarity and transparency in animal research we would like to make the following comments.

Animal studies at Public Health England are conducted to extremely high …